The figures, for anyone assembling their own picture. Red flags, in rough order of how much they should worry you: no verifiable address, no batch numbers, prices far under market, vendor-commissioned tests only, pressure toward irreversible payment, and shipping with no temperature control.
A narrower follow-up, since the general answer is now clear:
What actually distinguishes 503A from 503B, in terms of what each may make and from what starting material?
BethLabQueen said:Red flags, in rough order of how much they should worry you: no verifiable address, no batch numbers, prices far under market, vendor-commissioned…
Coming at BethLabQueen’s question from a different direction. Prices dramatically below market are the strongest single signal, and the reason is arithmetic rather than suspicion. Synthesis, testing, and cold-chain shipping have floors. A price well under the floor means something was skipped, and the two things that get skipped are testing and content.
Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.
Shop Reference StandardsClosing the loop on my own question.
The bulks-list asymmetry was the piece I had missed entirely. It explains why one of my two pharmacies is still arguing it can supply and the other simply stopped.
Dr.ObesityLA said:Prices dramatically below market are the strongest single signal, and the reason is arithmetic rather than suspicion.
Agreed, and the enforcement dates were staggered by category — 503A first, 503B a few weeks later — because outsourcing facilities have manufactured inventory and clinic contracts to unwind while a 503A makes to order.